DICE Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Kevin Judice
- Full Time Employees
- 71
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 279 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Sep 15, 2021
- CIK
- 0001645569
- Website
- dicemolecules.com
- Similar Companies
- Business
- DICE Therapeutics, Inc., a biopharmaceutical company and wholly owned subsidiary of Eli Lilly and Company, leverages its proprietary DELSCAPE platform to discover and develop novel oral small molecule therapeutics that modulate protein-protein interactions for chronic diseases in immunology and other areas; core pipeline assets include DC-853, an oral interleukin-17 (IL-17) antagonist advancing for psoriasis and other autoimmune indications with improved potency and metabolic stability relative to prior candidates; earlier programs target alpha4 beta7 integrin for inflammatory bowel disease, alphaV beta1/beta6 integrins for idiopathic pulmonary fibrosis, and a programmed death-ligand 1 initiative in immuno-oncology. The company, founded in 2013 and headquartered in South San Francisco, California, operates primarily in the United States with a focus on validated biologic targets to deliver orally bioavailable alternatives to injectable therapies for patients with immunology-driven conditions. Eli Lilly completed its $2.4 billion acquisition of DICE in August 2023, integrating the DELSCAPE platform and pipeline into Lilly's immunology portfolio; in October 2024, Lilly discontinued development of lead candidate DC-806 in psoriasis to prioritize DC-853, reflecting strategic optimization of the oral IL-17 program.
Lilly Completes Acquisition of DICE Therapeutics
Lilly Announces Extension of Tender Offer to Acquire DICE
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement
Eli Lilly Buys DICE Therapeutics for $2.4 Billion
Markets Fall at Midday, Pulled Lower by Energy Stocks
Why Shares of Dice Therapeutics Are Skyrocketing Tuesday
2 Biotech Stocks For Your June 2023 Watchlist
Options Traders Blast Dice Therapeutics Stock After Buyout
Why Is Dice Therapeutics (DICE) Stock Up 38% Today?
Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover
2 Biopharma Stocks Making Big Moves Tuesday
Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push